|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 35/00 | |
| A61K 39/395 | |||
| A61K 39/00 | |||
| A61K 31/33 | |||
| A61K 35/15 | |||
| A61K 45/06 | |||
| A61P 7/00 | |||
| A61K 31/4745 | |||
| A61K 31/713 | |||
| A61K 31/519 | |||
| C12N 5/0786 |
| (11) | Number of the document | 3247464 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16740762.6 |
| Date of filing the European patent application | 2016-01-21 | |
| (97) | Date of publication of the European application | 2017-11-29 |
| (45) | Date of publication and mention of the grant of the patent | 2019-09-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/014334 |
| Date | 2016-01-21 |
| (87) | Number | WO 2016/118754 |
| Date | 2016-07-28 |
| (30) | Number | Date | Country code |
| 201562106050 P | 2015-01-21 | US |
| (72) |
WEISSMAN, Irving L., US
FENG, Mingye, US
VOLKMER, Jens-Peter, US
|
| (73) |
The Board of Trustees of the Leland Stanford Junior University,
Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038,
US
|
| (54) | USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS |
| USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS |